Streetbeat News

Products Services

ABUS

BRNS

Barinthus Biotherapeutics (BRNS) announced data from two HBV clinical trials at The American Association for the Study of Liver Diseases. The data includes results from a Phase 2b trial of VTP-300 combined with a low-dose anti-PD-1 antibody and standard-of-care (SoC) nucleos(t)ide analogue (NUC) therapy. Additionally, interim data from a Phase 2a trial combining Arbutus Biopharma Corporation’s (ABUS) RNAi therapeutic candidate, imdusiran, with Barinthus Bio’s VTP-300 and SoC NUC therapy was presented. The initial data shows meaningful reductions of HBsAg levels.

Portfolio Pulse from Charles Gross

November 09, 2023 | 9:27 pm

CELH

KO

MNST

PEP

STZ

Prime, a sports drink brand launched by YouTubers Logan Paul and KSI, has sold one billion bottles in two years, posing potential competition to beverage giants Coca-Cola and PepsiCo. Prime has secured key retail locations and endorsement deals, contributing to its rapid growth. Coca-Cola and PepsiCo have stakes in Monster Beverage Corporation and Celsius Holdings respectively, both of which compete with Prime in the energy drink market. Prime's success could make it an acquisition target for larger beverage companies.

Portfolio Pulse from Chris Katje

November 09, 2023 | 9:03 pm

TAK

Takeda Pharmaceutical Company Limited (TAK) has received approval from the U.S. Food and Drug Administration (FDA) for ADZYNMA, a recombinant ADAMTS13 enzyme replacement therapy for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP). This is the first and only FDA-approved treatment for cTTP, an ultra-rare, chronic blood clotting disorder. The approval was supported by data from a Phase 3 trial and a continuation trial. This development does not affect Takeda's consolidated forecast for the fiscal year ending March 31, 2024.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 8:56 pm

LAZR

MBLY

PSNY

Polestar, Mobileye, and Luminar have announced plans to equip the Polestar 4 with Luminar LiDAR and Mobileye's Chauffeur system. This will be the first passenger vehicle to be based on Mobileye's Chauffeur system equipped with Luminar LiDAR. The integration aims to enhance safety and future autonomous driving capabilities of Polestar 4. The partnership between Luminar and Mobileye has been ongoing for years, focusing on Level 4 Mobility-as-a-Service (MaaS) product and Autonomous Vehicle series solution.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 8:50 pm

APD

Air Products (NYSE:APD) has partnered with Chengzhi Shareholding Co. Ltd. to accelerate transport decarbonization in China's Yangtze River Delta. The companies have launched their first commercial-scale hydrogen fueling station in Changshu city, Jiangsu province. The station fuels hydrogen fuel cell trucks of various multinational and domestic companies, including Budweiser China, Yum China, the logistics service provider of Nestle China and JD Logistics, to pilot zero-emission logistics operations.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 8:43 pm

NFLX

VZ

Netflix and Warner's Max have partnered with Verizon to offer a discounted streaming bundle. Verizon will offer ad tiers of both services for about $10 a month combined, instead of $17.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 8:26 pm

PSNY

Polestar, the Swedish electric vehicle manufacturer, has announced plans to expand its manufacturing footprint to South Korea. The company will start production of its Polestar 4 model in Busan in 2025. PSNY, the US-listed SPAC that is set to merge with Polestar, is mentioned in the article.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 7:17 pm

GS

Goldman Sachs is reportedly working on a dozen projects that will incorporate generative AI into its business practices, according to the Reuters NEXT Conference.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 6:58 pm

NIO

VWAGY

Volkswagen AG plans to launch a sub-$35,000 electric vehicle in the U.S. within the next three to four years. The company is considering potential production locations in the U.S. or Mexico and is exploring the localization of battery pack assembly. Meanwhile, Chinese car manufacturer NIO Inc is still considering a 2025 entry into North America, with the need to establish a robust infrastructure and potential partnerships being key factors.

Portfolio Pulse from Shivani Kumaresan

November 09, 2023 | 6:49 pm

LLY

NVO

The FDA has approved Eli Lilly's Zepbound, the first and only obesity treatment. The drug is expected to be available in the U.S. by the end of the year at a price 20% lower than Novo Nordisk's semaglutide 2.4 mg injection for weight loss. BMO Capital predicts the obesity market could reach $70 billion in the U.S. and $100 billion worldwide by 2035. Lilly's dual branding of tirzepatide as Mounjaro for Type 2 Diabetes and Zepbound for weight management is seen as a strategic move for long-term competitiveness. Truist remains bullish on Zepbound/Mounjaro, predicting peak global sales of $44 billion.

Portfolio Pulse from Vandana Singh

November 09, 2023 | 6:44 pm